



UNITED STATES OF AMERICA
FEDERAL TRADE COMMISSION
WASHINGTON, D.C. 20580

Office of the Secretary

August 28, 2012

Bilal Sayyed, Esq.
Counsel for Spectrum Pharmaceuticals, Inc.
Kirkland & Ellis LLP
665 Fifteenth Street, N.W.
Washington, D.C. 20005

Re: Proposed Acquisition of Allos Therapeutics, Inc. by Spectrum Pharmaceuticals, Inc., FTC File No. 121-0108

Dear Mr. Sayyed:

The Federal Trade Commission's Bureau of Competition has been conducting a nonpublic investigation to determine whether the proposed acquisition of Allos Therapeutics, Inc. by Spectrum Pharmaceuticals, Inc. may violate Section 7 of the Clayton Act or Section 5 of the Federal Trade Commission Act.

Upon further review of this matter, it now appears that no further action is warranted by the Commission at this time. Accordingly, the investigation has been closed. This action is not to be construed as a determination that a violation may not have occurred, just as the pendency of an investigation should not be construed as a determination that a violation has occurred. The Commission reserves the right to take such further action as the public interest may require.

By direction of the Commission.

April J. Tabor
Acting Secretary